	US 11,872,249 B2
	Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain
Barbara Brannetti, Cambridge, MA (US); Jennifer Brogdon, Sudbury, MA (US); Boris Engels, Arlington, MA (US); Brian Walter Granda, Salisbury, MA (US); Lu Huang, West Roxbury, MA (US); Ming Lei, Acton, MA (US); Na Li, Cambridge, MA (US); Jimin Zhang, Chestnut Hill, MA (US); Carla Patricia Pinto Guimaraes, Boston, MA (US); Saar Gill, Philadelphia, PA (US); Marco Ruella, Ardmore, PA (US); and Regina M. Young, Bryn Mawr, PA (US)
Assigned to Novartis AG, Basel (CH); and The Trustees of the University of Pennsylvania, Philadelphia, PA (US)
Filed by Novartis AG, Basel (CH); and The Trustees of the University of Pennsylvania, Philadelphia, PA (US)
Filed on Apr. 30, 2021, as Appl. No. 17/246,351.
Application 17/246,351 is a division of application No. 16/664,223, filed on Oct. 25, 2019, granted, now 11,026,976.
Application 16/664,223 is a division of application No. 15/727,402, filed on Oct. 6, 2017, granted, now 10,525,083, issued on Jan. 7, 2020.
Claims priority of provisional application 62/405,520, filed on Oct. 7, 2016.
Prior Publication US 2022/0387486 A1, Dec. 8, 2022
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61K 35/17 (2015.01); C12N 15/85 (2006.01)

CPC A61K 35/17 (2013.01) [A61K 38/1774 (2013.01); A61P 35/00 (2018.01); C07K 16/2803 (2013.01); C07K 16/2887 (2013.01); C07K 16/2896 (2013.01); C12N 15/85 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01)]

38 Claims

1. A method of treating a cancer, wherein said method comprises administering to the mammal an effective amount of a plurality of immune effector cells expressing an isolated chimeric antigen receptor (CAR), wherein the plurality of immune effector cells comprise T cells, NK cells, or both T cells and NK cells, wherein the CAR comprises a CD20 binding domain, a transmembrane domain, and an intracellular signaling domain, and wherein the CD20 binding domain comprises a light chain complementarity determining region 1 (LCDR1), light chain complementarity determining region 2 (LCDR2), light chain complementarity determining region 3 (LCDR3), heavy chain complementarity determining region 1 (HCDR1), heavy chain complementarity determining region 2 (HCDR2), and heavy chain complementarity determining region 3 (HCDR3), wherein the LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR3 comprise:

(i) SEQ ID NOs: 147, 148, 149, 136, 137, and 138, respectively;

(ii) SEQ ID NOs: 150, 151, 152, 139, 140, and 141, respectively;

(iii) SEQ ID NOs: 153, 154, 155, 142, 143, and 144, respectively;

(iv) SEQ ID NOs: 929, 930, 931, 926, 927, and 928, respectively;

(v) SEQ ID NOs: 228, 229, 230, 217, 218, and 219, respectively;

(vi) SEQ ID NOs: 231, 232, 233, 220, 221, and 222, respectively;

(vii) SEQ ID NOs: 234, 235, 236, 223, 224, and 225, respectively; or

(viii) SEQ ID NOs: 944, 945, 988, 941, 942, and 943, respectively.